XAIR Beyond Air (XAIR) Insider Trading, Ownership & Congress Trades
Medical Devices · Surgical & medical instruments & apparatus · CIK 0001641631
Cluster · 3 insidersC-suite buying · 2
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
7
13F, latest reported quarter
What the filings say about XAIR
Insiders, 180 days
+$287.3K net bought
3 buyers
Beyond Air insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Beyond Air, Inc. insiders bought a net $287.3K of stock across 69 Form 4 purchases and sales, with 3 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Oct 1, 2026.
- The trade is 1.8% of the 148,000 shares held after it.
- No other insider bought within 30 days.
- 7 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Lin Yi-Chien bought about $5.8K of XAIR on Oct 13, 2026; 7 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Sep 30, 2026.
- The trade is 10.6% of the 145,393 shares held after it.
- No other insider bought within 30 days.
- 7 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Lin Yi-Chien bought about $43.1K of XAIR on Oct 1, 2026; 7 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Sep 29, 2026.
- The trade is 1.5% of the 130,000 shares held after it.
- No other insider bought within 30 days.
- 7 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Lin Yi-Chien bought about $5.4K of XAIR on Sep 30, 2026; 7 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 2.3% of the 128,000 shares held after it.
- No other insider bought within 30 days.
- 7 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Lin Yi-Chien bought about $8.1K of XAIR on Sep 29, 2026; 7 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 100.0% of the 4,340 shares held after it.
- 1 other insider bought within 30 days.
- 7 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer MOORHEAD DANIEL J bought about $25.0K of XAIR on Jul 29, 2026, the largest insider purchase at the company since 2025; 1 other insider bought within 30 days and 7 funds added in the latest 13F quarter.69 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$287.3K over 180 days
+$62.4K over 90 days · +$62.4K of it by a 10%+ holder
more than 82% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
7 funds bought in last quarter
below 92% of Medical Devices
Revenue
+107.3% year over year
more than 93% of Medical Devices
Margin
-433.0% net margin
below 91% of Medical Devices
Buybacks
no share repurchases reported
Short interest
7.8% of the float short (float per yahoo 2026-10-27) · 1.3 days to cover · settled 2026-10-15
more than 72% of Medical Devices
The situation: each line is one rule over one dataset
3 insiders independently bought a net $287.3K while the stock fell 78% over six months, with no planned sales queued.
1 clinical trial was terminated, suspended or withdrawn in the last 90 days.
What changed in the last 30 days
Oct 14Insider Lin Yi-Chien bought $62.4K (4 trades, Sep 29 to Oct 13)
Watch XAIR
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-94.7%12M
Insider buy
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns XAIR: institutional holders (13F)
13F holdings, latest reported quarter
464,161 sh
$207.0K
274,208 sh
$122.3K
151,550 sh
$61.5K
112,242 sh
$50.0K
86,489 sh
$38.6K
Congress trades in XAIR
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
XAIR planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
XAIR mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$47.3K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$28.0K position · as of 2026-06-30
0.0%
Fidelity Nasdaq Composite Index Fund
$781 position · as of 2026-05-31
0.0%
Fidelity Total Market Index Fund
$3.7K position · as of 2026-05-31
0.0%
Fidelity Series Total Market Index Fund
$2.9K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
1 registered trials, 0 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 1
0 active
What changed recently
A Study to Assess the Safety and Efficacy of UNO - Ultra High Concentration Nitric Oxide
2026-10-14 · Completion moved 2025-05-30 → 2025-08-31
Phase 1
A Study to Assess the Safety and Efficacy of UNO - Ultra High Concentration Nitric Oxide
2026-10-14 · Unknown → Terminated · study stopped due to changes of sponsor strategy and resource allocation. No safety issues were identified
Phase 1
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Steve Lisi has served as our PEO since July 1, 2017.
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$816.1K
-$792.2K
$435.1K
-96%
n/a
2023
$1.7M
-$4.1M
$875.5K
-74%
n/a
2022
$6.9M
$6.8M
$2.2M
+1%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
3 insiders reported buying shares.
The record shows a net $287.3K bought by insiders over 180 days, 7 funds added last quarter. Each figure is a federal filing, dated the day it went public.
XAIR financials
Revenue growth
+107.3%
XBRL, annual
Net margin
-433.0%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$7.7M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM XAIR
| FY Mar 2026 | $7.7M |
| FY Mar 2025 | $3.7M |
| FY Mar 2024 | $1.2M |
| FY Mar 2023 | $873.4K |
| FY Mar 2022 | $873.4K |
| Jun 2026 | $1.8M |
| Mar 2026 | $1.9M |
| Dec 2025 | $2.2M |
| Sep 2025 | $1.8M |
| Jun 2025 | $1.8M |
| Mar 2025 | $1.2M |
| Dec 2024 | $1.1M |
| Sep 2024 | $798.0K |
At each fiscal year end
Single quarter
Net margin, TTM
-449.8%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM XAIR
| FY Mar 2026 | -447.1% |
| FY Mar 2025 | -1,308% |
| FY Mar 2024 | -5,547% |
| FY Mar 2023 | n/a |
| FY Mar 2022 | n/a |
| Jun 2026 | -448.8% |
| Mar 2026 | -596.1% |
| Dec 2025 | -334.4% |
| Sep 2025 | -436.7% |
| Jun 2025 | -437.0% |
| Mar 2025 | -858.3% |
| Dec 2024 | -1,216% |
| Sep 2024 | -1,674% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$19.6M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM XAIR
| FY Mar 2026 | -$19.2M |
| FY Mar 2025 | -$44.1M |
| FY Mar 2024 | -$61.8M |
| FY Mar 2023 | -$36.9M |
| FY Mar 2022 | n/a |
| Jun 2026 | -$5.2M |
| Mar 2026 | -$5.5M |
| Dec 2025 | -$4.3M |
| Sep 2025 | -$4.7M |
| Jun 2025 | -$4.7M |
| Mar 2025 | -$8.5M |
| Dec 2024 | -$8.3M |
| Sep 2024 | -$14.5M |
At each fiscal year end
Single quarter
Debt to equity
5.94x
long-term 2024-12-31 (18 months older than the period end) plus current 2017-03-31 (112 months older than the period end); equity 2026-06-30
Debt to equity XAIR
| FY Mar 2026 | 1.94x |
| FY Mar 2025 | 0.87x |
| FY Mar 2024 | 0.70x |
| FY Mar 2023 | 0.01x |
| FY Mar 2022 | 0.00x |
| Jun 2026 | 5.94x |
| Mar 2026 | 1.94x |
| Dec 2025 | 1.46x |
| Sep 2025 | 0.93x |
| Jun 2025 | 1.20x |
| Mar 2025 | 0.87x |
| Dec 2024 | 0.67x |
| Sep 2024 | 0.45x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-1.56x
TTM operating cash flow over long-term 2024-12-31 (18 months older than the period end) plus current 2017-03-31 (112 months older than the period end)
Cash flow to debt XAIR
| FY Mar 2026 | -1.53x |
| FY Mar 2025 | -3.22x |
| FY Mar 2024 | -3.20x |
| FY Mar 2023 | -145.41x |
| FY Mar 2022 | n/a |
| Jun 2026 | -1.56x |
| Mar 2026 | -1.53x |
| Dec 2025 | -1.70x |
| Sep 2025 | -1.99x |
| Jun 2025 | -2.74x |
| Mar 2025 | -3.22x |
| Dec 2024 | -3.54x |
| Sep 2024 | -3.84x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-580.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity XAIR
| FY Mar 2026 | -348.4% |
| FY Mar 2025 | -251.0% |
| FY Mar 2024 | -204.2% |
| FY Mar 2023 | -100.9% |
| FY Mar 2022 | -83.7% |
| Jun 2026 | -580.0% |
| Mar 2026 | -348.4% |
| Dec 2025 | -255.1% |
| Sep 2025 | -188.7% |
| Jun 2025 | -337.5% |
| Mar 2025 | -251.0% |
| Dec 2024 | -293.1% |
| Sep 2024 | -221.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-113.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets XAIR
| FY Mar 2026 | -104.9% |
| FY Mar 2025 | -111.4% |
| FY Mar 2024 | -102.3% |
| FY Mar 2023 | -66.5% |
| FY Mar 2022 | -61.8% |
| Jun 2026 | -113.4% |
| Mar 2026 | -104.9% |
| Dec 2025 | -92.7% |
| Sep 2025 | -91.8% |
| Jun 2025 | -117.9% |
| Mar 2025 | -111.4% |
| Dec 2024 | -131.0% |
| Sep 2024 | -107.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital XAIR
| FY Mar 2026 | n/a |
| FY Mar 2025 | n/a |
| FY Mar 2024 | n/a |
| FY Mar 2023 | n/a |
| FY Mar 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-113.4%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed XAIR
| FY Mar 2026 | -107.7% |
| FY Mar 2025 | -126.4% |
| FY Mar 2024 | -133.5% |
| FY Mar 2023 | -75.7% |
| FY Mar 2022 | -65.0% |
| Jun 2026 | -113.4% |
| Mar 2026 | -107.7% |
| Dec 2025 | -96.0% |
| Sep 2025 | -91.5% |
| Jun 2025 | -132.5% |
| Mar 2025 | -126.4% |
| Dec 2024 | -145.0% |
| Sep 2024 | -121.8% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing XAIR
| FY Mar 2026 | n/a |
| FY Mar 2025 | n/a |
| FY Mar 2024 | n/a |
| FY Mar 2023 | n/a |
| FY Mar 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$8.5M
market value at close 2026-10-27 on 2026-08-12 shares, plus long-term 2024-12-31 (18 months older than the period end) plus current 2017-03-31 (112 months older than the period end), minus cash 2026-06-30
Enterprise value XAIR
| FY Mar 2026 | $150.4M |
| FY Mar 2025 | $9.6B |
| FY Mar 2024 | $25.1B |
| FY Mar 2023 | $81.2B |
| FY Mar 2022 | $79.6B |
| Jun 2026 | $134.9M |
| Mar 2026 | $150.4M |
| Dec 2025 | $121.5M |
| Sep 2025 | $243.6M |
| Jun 2025 | $6.4B |
| Mar 2025 | $9.6B |
| Dec 2024 | $10.4B |
| Sep 2024 | $7.2B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-926.1%
TTM free cash flow over market value at close 2026-10-27
FCF yield XAIR
| FY Mar 2026 | -13.2% |
| FY Mar 2025 | -0.5% |
| FY Mar 2024 | -0.2% |
| FY Mar 2023 | -0.0% |
| FY Mar 2022 | n/a |
| Jun 2026 | -15.2% |
| Mar 2026 | -13.2% |
| Dec 2025 | -19.0% |
| Sep 2025 | -10.8% |
| Jun 2025 | -0.6% |
| Mar 2025 | -0.5% |
| Dec 2024 | -0.5% |
| Sep 2024 | -0.8% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing XAIR
| FY Mar 2026 | n/a |
| FY Mar 2025 | n/a |
| FY Mar 2024 | n/a |
| FY Mar 2023 | n/a |
| FY Mar 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2026-03 | 2025-03 | 2024-03 | 2023-03 | |
|---|---|---|---|---|
| Revenue | $7.7M | $3.7M | $1.2M | n/a |
| Gross profit | $252.0K | -$1.7M | -$1.3M | -$555.0K |
| Operating income | -$29.0M | -$44.5M | -$63.0M | -$52.1M |
| Net income | -$34.3M | -$48.5M | -$64.3M | -$55.8M |
| EPS (diluted) | -4.01 | -13.77 | -1.82 | -1.86 |
| Operating cash flow | -$18.1M | -$38.2M | -$56.0M | -$33.0M |
| Cash | $6.7M | $4.7M | $11.4M | $29.2M |
| Long-term debt | n/a | n/a | $17.5M | $200.0K |
SEC XBRL, fiscal years, as known on 2026-10-28
XAIR Stock Sonar score 6/7 axes
Find similar shapesCompareXAIR ranks highest on growth (93rd percentile) and insider conviction (84th), and lowest on institutional and government (8th), among Medical Devices peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
XAIR filings, in plain words
Are Beyond Air insiders buying or selling XAIR?
In the 180 days to 2026-10-28, Beyond Air insiders were net buyers, a net $287.3K across purchases and sales reported on Form 4, by 3 buyers.
Read the full summary
In the 180 days to 2026-10-28, Beyond Air insiders were net buyers of XAIR, a net $287.3K across purchases and sales reported on Form 4 by 3 buyers. 3 insiders reported purchases in that window. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
